Atropos Health, a Palo Alto, CA-based pioneer in translating real-world scientific information into high-quality personalised real-world proof for care, raised $33m in Collection B funding.
The spherical was led by Valtruis, with participation from new strategic buyers together with Cencora Ventures, McKesson Ventures, and Merck GHI Fund, together with present buyers Breyer Capital, Emerson Collective, and Presidio Ventures.
on the heels of the adoption of its Generative AI platform (GENEVA OSTM) by healthcare establishments, information platforms, analysis establishments, Life Sciences corporations and extra.
Based in 2019 as a spin-out of the “Inexperienced Button” expertise developed at Stanford College by Brigham Hyde Ph.D., Nigam Shah MBBS, Ph.D., and Saurabh Gombar M.D., Ph.D., Atropos Well being is the developer of GENEVA OSTM, the working system for fast healthcare proof throughout a community of real-world information.
Healthcare and life science organizations work with Atropos Well being to shut proof gaps from bench to bedside, enhancing particular person affected person outcomes with data-driven care, expediting analysis that advances the sector of medication, and extra.
The corporate’s portfolio of evidence-generating functions helps whole-person care and value-based efficiency and has lengthy been utilized by Atropos Well being companions together with Arcadia. By means of Atropos Well being, healthcare organizations are in a position to speed up applicable scientific decision-making to drive high-value, low-cost take care of sufferers based mostly on their distinctive physiology.
FinSMEs
23/05/2024
